Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/31981
Title: | What have we learned from clinical trials on prevention?. | Authors: | Atkins R.C.;Kerr P.G. ;Pellicano R. | Institution: | (Pellicano, Kerr, Atkins) Monash Medical Centre, Melbourne, Vic., Australia (Pellicano) Department of Nephrology, Monash Medical Centre, 246 Clayton Rd., Clayton, Vic. 3168, Australia | Issue Date: | 18-Apr-2005 | Copyright year: | 2005 | Publisher: | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | Place of publication: | United States | Publication information: | Kidney International, Supplement. 67 (94) (pp S-101-S-106), 2005. Date of Publication: April 2005. | Abstract: | The incidence of end-stage renal disease is increasing at an alarming rate. While diabetes is now the most common cause of renal failure, hypertension commonly coexists, exacerbating renal damage and the other vascular complications of diabetes. Clinical trials have shown the benefits of intervention strategies that target not only the retardation of renal disease, but also the primary prevention of the conditions known to cause renal damage. These strategies include: lifestyle modification programs to prevent diabetes and hypertension; aggressive treatment of established hypertension; combination antihypertensive regimens; and the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for additional renoprotection beyond that of blood pressure control. In addition, albuminuria and proteinuria have emerged as powerful predictors of progression of renal disease. The present paper reviews the results of available clinical trials and meta-analyses on these interventional strategies, and highlights the potential of albuminuria and proteinuria in predicting renal and cardiovascular outcomes. © 2005 by the International Society of Nephrology. | PubMed URL: | 15752224 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15752224] | ISSN: | 0098-6577 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/31981 | Type: | Conference Paper | Subjects: | vascular disease amlodipine/ct [Clinical Trial] amlodipine/dt [Drug Therapy] angiotensin 2 receptor antagonist/ct [Clinical Trial] angiotensin 2 receptor antagonist/cb [Drug Combination] angiotensin 2 receptor antagonist/dt [Drug Therapy] antihypertensive agent/ct [Clinical Trial] antihypertensive agent/dt [Drug Therapy] calcium channel blocking agent/cb [Drug Combination] calcium channel blocking agent/dt [Drug Therapy] candesartan/ct [Clinical Trial] candesartan/dt [Drug Therapy] captopril/dt [Drug Therapy] dipeptidyl carboxypeptidase inhibitor/ct [Clinical Trial] dipeptidyl carboxypeptidase inhibitor/cb [Drug Combination] dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy] irbesartan/ct [Clinical Trial] irbesartan/dt [Drug Therapy] lisinopril/ct [Clinical Trial] lisinopril/dt [Drug Therapy] losartan/dt [Drug Therapy] ramipril/dt [Drug Therapy] losartan/ct [Clinical Trial] clinical trial conference paper diabetes mellitus disease course human hypertension/dt [Drug Therapy] hypertension/pc [Prevention] *kidney failure/dt [Drug Therapy] *kidney failure/pc [Prevention] kidney injury lifestyle priority journal proteinuria renal protection priority journal proteinuria renal protection vascular disease clinical trial *kidney failure / *drug therapy / *prevention hypertension / drug therapy / prevention conference paper lifestyle human disease course diabetes mellitus kidney injury |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.